Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.

Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther. 2014 Apr; 13(4):902-15.

View in: PubMed

subject areas

Animals
Antibodies, Monoclonal
Antineoplastic Agents
Breast Neoplasms
Carcinoma, Ductal, Breast
Cell Line, Tumor
Female
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Mammary Neoplasms, Experimental
Membrane Glycoproteins
Mice
Mice, Inbred BALB C
Signal Transduction
Tissue Array Analysis
Xenograft Model Antitumor Assays

authors with profiles

Madhuri Wadehra, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support